Abstract
Eculizumab (a terminal complement inhibitor) demonstrated efficacy in reducing relapse risk and eliciting clinical improvements in the phase 3, randomised, double-blind PREVENT (NCT01892345) and REGAIN (NCT01997229) studies and their open-label extensions (NCT02003144 and NCT02301624, respectively) in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor antibody-positive generalised myasthenia gravis (AChR+ gMG), respectively. The aim of this analysis was to compare infection rates for eculizumab vs placebo according to number of concomitant immunosuppressive therapies (ISTs) during these studies.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
